Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the
Rna Interference (rnai) Drug Delivery Market
Request Now !
RNA Interference (RNAi) is a biological process in which RNA molecules inhibit the gene expression. Study of RNAi helps in the analysis of gene functions in eukaryotic organisms.
The global RNAi drug delivery market is driven by several factors such as increasing research activities in the field of RNA therapeutics, growing number of academic research institutes, and increasing prevalence of chronic disorders such as cardiac abnormalities and cancer. However, high costs of research and threat of failure will restrain the market growth. Increasing research in the field of nanotechnology will provide opportunities for the market growth.
The report segments the global RNAi drug delivery market based on the type of drug delivery technology, application, and region. Based on type of drug delivery technology, it is segmented into nanoparticle drug delivery technology, pulmonary drug delivery technology, nucleic acid drug delivery technology, and aptamer drug delivery technology. Based on application it is segmented into infectious diseases, cardiology, oncology, neurology, ophthalmology, and metabolic disorders. Geographically, it has been analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Key players that operate in the market include Tekmira Pharmaceuticals Corp., Alnylam Pharmaceuticals Inc., Merck & Co. Inc., Isis Pharmaceuticals, Inc., Access Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Calondo Pharmaceuticals Inc., Marina Biotech Inc., RXi Pharmaceuticals Corp., and Quark Pharmaceuticals Inc.
- The study provides an in-depth analysis of the global market with current trends and future estimations to elucidate imminent investment pockets.
- The report provides a quantitative analysis from 2016 to 2023, which is expected to enable stakeholders to capitalize on prevailing market opportunities.
- Competitive intelligence highlights the business practices followed by leading players across various regions.
- Comprehensive analysis of all geographic regions has been provided that helps determine prevailing opportunities in these regions.
- Key market players within the market have been profiled in the report and their strategies thoroughly analyzed, which helps in understanding the competitive outlook of the global market.
- Extensive analysis of the market has been conducted by closely following key product positioning and monitoring the top contenders within the market framework.
RNAInterference (RNAi) Drug Delivery Market KeySegments:
By Type of Drug Delivery Technology
- Nanoparticle Drug Delivery Technology
- Pulmonary Drug Delivery Technology
- Nucleic Acid Drug Delivery Technology
- Aptamer Drug Delivery Technology
- Infectious Diseases
- Metabolic Disorders
- North America
- Rest of Europe
- South Korea
- Rest of Asia-Pacific
- Saudi Arabia
- South Africa
- Rest of LAMEA
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.4.1. MARKET DYNAMICS
CHAPTER 4 RNAI DRUG DELIVERY MARKET, BY DRUG DELIVERY TECHNOLOGY
4.1.1. Market size and forecast
4.2. NANOPARTICLE DRUG DELIVERY TECHNOLOGY
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. PULMONARY DRUG DELIVERY TECHNOLOGY
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.4. NUCLIEC ACID DRUG DELIVERY TECHNOLOGY
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
4.5. APTAMER DRUG DELIVERY TECHNOLOGY
4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast
CHAPTER 5 RNAI DRUG DELIVERY MARKET, BY APPLICATION
5.1.1. Market size and forecast
5.2. INFECTIOUS DISEASES
5.2.1. Market size and forecast
5.3.1. Market size and forecast
5.4.1. Market size and forecast
5.5.1. Market size and forecast
5.6.1. Market size and forecast
5.7. METABOLIC DISORDERS
5.7.1. Market size and forecast
CHAPTER 6 RNAI DRUG DELIVERY MARKET, BY REGION
6.2. NORTH AMERICA
6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast
126.96.36.199. U.S. market size and forecast
188.8.131.52. Canada market size and forecast
184.108.40.206. Mexico market size and forecast
6.2.4. North America RNAi drug delivery market by drug delivery technology
6.2.5. North America RNAi drug delivery market by application
6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast
220.127.116.11. Germany market size and forecast
18.104.22.168. France market size and forecast
22.214.171.124. UK market size and forecast
126.96.36.199. Italy market size and forecast
188.8.131.52. Spain market size and forecast
184.108.40.206. Rest of Europe market size and forecast
6.3.4. Europe RNAi drug delivery market by drug delivery technology
6.3.5. Europe RNAi drug delivery market by application
6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast
220.127.116.11. Japan market size and forecast
18.104.22.168. China market size and forecast
22.214.171.124. Australia market size and forecast
126.96.36.199. India market size and forecast
188.8.131.52. South Korea market size and forecast
184.108.40.206. Taiwan market size and forecast
220.127.116.11. Rest of Asia-Pacific market size and forecast
6.4.4. Asia-Pacific RNAi drug delivery market by drug delivery technology
6.4.5. Asia-Pacific RNAi drug delivery market by application
6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast
18.104.22.168. Brazil market size and forecast
22.214.171.124. Turkey market size and forecast
126.96.36.199. Saudi Arabia market size and forecast
188.8.131.52. South Africa market size and forecast
184.108.40.206. Rest of LAMEA market size and forecast
6.5.4. LAMEA RNAi drug delivery market by drug delivery technology
6.5.5. LAMEA RNAi drug delivery market by application
CHAPTER 7 COMPANY PROFILES
7.1. TEKMIRA PHARMACEUTICALS CORP
7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments
7.2. ALNYLAM PHARMACEUTICALS INC.
7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments
7.3. MERCK & CO. INC.
7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments
7.4. ISIS PHARMACEUTICALS, INC.
7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments
7.5. ACCESS PHARMACEUTICALS INC.
7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments
7.6. DICERNA PHARMACEUTICALS INC.
7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments
7.7. CALONDO PHARMACEUTICALS INC.
7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments
7.8. MARINA BIOTECH INC.
7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments
7.9. RXI PHARMACEUTICALS CORP
7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments
7.10. QUARK PHARMACEUTICALS INC.
7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments